Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.40 |
| ▸ | HPGD | P15428 | 6/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | CASP1 | P29466 | 2/20 | 0.39 |
| ▸ | CASP7 | P55210 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23788051 | 0.88 | SMPD3 (0.41) | TGFBR1KDM4EHSD17B10NTRK1SMPD3 | |
| SCHEMBL18208219 | 0.84 | SMPD3 (0.54) | TGFBR1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL21998239 | 0.80 | TGFBR1 (0.44) | TGFBR1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL21997996 | 0.79 | NTRK1 (0.45) | TGFBR1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL10204204 | 0.77 | PDE2A (0.53) | TGFBR1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL16946890 | 0.77 | TGFBR1 (0.44) | TGFBR1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL461752 | 0.76 | TGFBR1 (0.51) | TGFBR1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL22763214 | 0.75 | KDM4E (0.53) | TGFBR1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL25162502 | 0.75 | TGFBR1 (0.50) | TGFBR1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL16718827 | 0.75 | TGFBR1 (0.50) | TGFBR1ALDH1A1KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TGFBR1 1014/4885ALDH1A1 2776/4885KDM4E 190/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TGFBR1 1014/4885ALDH1A1 2776/4885KDM4E 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.